Explore › Outcome › Statin therapy
Outcome

Statin therapy

Also known as: 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor prophylaxis Administration of prophylactic statin Administration of prophylactic statin (procedure) HMG-CoA reductase inhibitor prophylaxis Pharmacy claims for statin therapy Statin prophylaxis Statin prophylaxis (procedure) Statin therapy
3 findings 1 paper 3 related entities View in graph →

Related entities

interventions
Statins1
conditions
Atherosclerotic cardiovascular disease risk estimator plus1
studys
PMC80096951

Findings (27)

None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →

Papers (1)